Why You Should Care About Derivatives Reform

By Matt Kelly2010-06-21T10:57:00

lock icon THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.

Become a Member

News and analysis for the well-informed compliance or audit exec. Select an option and click continue.

Annual Membership $499 Value offer

Full price one year membership with auto-renewal.

Membership $599

One-year only, no auto-renewal.

Access CW Newsletters and CPE webcasts. REGISTER FOR LIMITED FREE ACCESS

Already a Compliance Week member?

Article
Many Companies Unprepared for Coming Derivatives Regulation

2013-02-20T00:00:00Z By Tammy Whitehouse
Article
As Regulators Tinker With New Rules for Derivatives, a Deadline Looms

2011-06-14T00:00:00Z By Arielle Bikard
News Brief
Becton Dickinson pays $175M for misleading investors about flawed IV pump system

2024-12-18T18:08:00Z By Adrianne Appel

Becton Dickinson medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission said.